Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference
Connect Biopharma (Nasdaq: CNTB) announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:00 am ET. The event aims to discuss the company's advancements in therapies for chronic inflammatory diseases, including their lead products CBP-201 and CBP-307. A live webcast can be accessed on Connect Biopharma's Investor Relations page, with a replay available post-event. The company is dedicated to innovative T cell-driven research.
- None.
- None.
Insights
Analyzing...
SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO of Connect Biopharma, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 am ET.
A live webcast of this fireside chat will be available on the Company’s Investor Relations page accessible here: https://investors.connectbiopharm.com/. A replay will be available on the Company’s website following the event.
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.
Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) and is currently being evaluated in clinical trials for the treatment of atopic dermatitis (AD) and asthma and in development for chronic rhinosinusitis with nasal polyps (CRSwNP). Our second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) that is in development for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we are developing CBP-174, a peripherally restricted antagonist of histamine receptor 3, for the treatment of pruritus associated with skin inflammation.
With headquarters in China, additional operations in the United States and Australia, and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com.
IR/PR CONTACTS:
Lazar FINN Partners
David Carey (IR)
T: +1-(212) 867-1768
david.carey@finnpartners.com
Erich Sandoval (Media)
+1-(646) 871-8482 or +1-(917) 497-2867
erich.sandoval@finnpartners.com
Corporate Contacts:
info@connectpharm.com
FAQ
What is the date and time of the Connect Biopharma fireside chat?
Who will represent Connect Biopharma at the Jefferies Virtual Healthcare Conference?
Where can I watch the Connect Biopharma fireside chat?
What is Connect Biopharma's focus in biopharmaceuticals?
What are the lead product candidates of Connect Biopharma?
